Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms.

Vogrin A, Besic H, Besic N, Music MM.

Radiol Oncol. 2016 Jul 19;50(3):269-73. doi: 10.1515/raon-2016-0025. eCollection 2016 Sep 1.

2.

Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Shawky M, Sakr M.

Indian J Surg. 2016 Feb;78(1):41-8. doi: 10.1007/s12262-015-1381-x. Epub 2015 Oct 30. Review.

3.

Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience.

Besic N, Schwarzbartl-Pevec A, Vidergar-Kralj B, Crnic T, Gazic B, Marolt Music M.

BMC Cancer. 2016 Feb 26;16:162. doi: 10.1186/s12885-016-2179-3.

4.
5.
6.

PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression.

Cerutti JM, Oler G, Delcelo R, Gerardt R, Michaluart P Jr, de Souza SJ, Galante PA, Huang P, Riggins GJ.

J Clin Endocrinol Metab. 2011 Jan;96(1):E151-60. doi: 10.1210/jc.2010-1318. Epub 2010 Oct 6.

7.

Age and tumor size predicts lymph node involvement in Hürthle Cell Carcinoma.

Guerrero MA, Suh I, Vriens MR, Shen WT, Gosnell J, Kebebew E, Duh QY, Clark OH.

J Cancer. 2010 Jun 2;1:23-6.

8.

Hurthle cell tumours of the thyroid. Personal experience and review of the literature.

Barnabei A, Ferretti E, Baldelli R, Procaccini A, Spriano G, Appetecchia M.

Acta Otorhinolaryngol Ital. 2009 Dec;29(6):305-11. Review.

9.

Conservative management of well-differentiated thyroid cancer.

Hassanain M, Wexler M.

Can J Surg. 2010 Apr;53(2):109-18.

Supplemental Content

Support Center